Session

• A multidisciplinary panel of clinicians will share best practice around the current place of androgen deprivation therapy (ADT) in the treatment of hormone-sensitive prostate cancer across the different stages of the disease
 – To include treatment adjuvant to surgery and radiation
 – In combination with chemotherapy
• Highlight the differences in mechanism of action and compare efficacy and safety profiles of different ADT agents
• Discuss future directions in hormonal treatment of prostate cancer